Survival Factors in IDH-Wildtype Glioblastoma: Insights from a Comprehensive Real-World Cohort Study on Clinical, Molecular, and Immunological Aspects Following Radiotherapy

1

IDH-wildtype glioblastoma has a median survival of 8 to 20 months despite treatment, highlighting the need for improved prognostic models.
2

This study is the largest single-institution analysis evaluating survival factors in glioblastoma patients treated with modern radiotherapy and temozolomide.
3

Radiation-induced lymphopenia (RIL) is identified as a negative prognostic factor for survival in glioblastoma patients receiving standard chemoradiotherapy.
4

The study aims to clarify independent prognostic factors, including clinical, molecular, and hematologic predictors of survival in glioblastoma.
5

Real-world data often show inferior survival outcomes compared to clinical trials, emphasizing the importance of population-specific analyses.

Journal Of Neuro-Oncology (Springer)

by Cole Friedes, Melanie Berger, Lauren Linkowski, Casey Hollawell, Harper Hubbeling, Daniel Alexander, Goldie Kurtz, Robert A. Lustig, Jay F. Dorsey, Arati S. Desai, Richard E. Phillips, Steven Brem, Christos Davatzikos, MacLean Nasrallah, Donald M. O’Rourke, Christina Jackson, Nduka M. Amankulor, Michelle Alonso-Basanta, Suyash Mohan, Stephen J. Bagley, Emily S. Lebow
April 25, 2026

1